@article{IR,
      author = {Khosroyani, Homma M. and Klug, Lillian and Heinrich,  Michael},
      url = {http://digitalcollections.ohsu.edu/record/9219},
      title = {Primary Imatinib resistance in PDGFRA-mutant GIST},
      publisher = {Oregon Health and Science University},
      abstract = {Gastrointestinal stromal tumor (GIST) is the most common  sarcoma of the GI tract. The second most common type of  GIST is driven by oncogenic mutations in PDGFRA, of which  there are 50+ different kinase domain mutations reported.  82% of these occur in the kinase activation loop (AL), with  the majority being a single point mutation, D842V.  PDGFRA-D842V is notoriously resistant to conventional  tyrosine kinase inhibitors approved for GIST, including  imatinib. However, it isn't known how GIST with other  PDGFRA AL mutations, which include numerous complex indels,  would clinically respond to imatinib.},
      number = {IR},
      doi = {https://doi.org/10.6083/8w32r639w},
      recid = {9219},
      address = {2021},
}